Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Tesaro, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Tesaro, Inc. - Product Pipeline Review - 2014', provides an overview of the Tesaro, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Tesaro, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Tesaro, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Tesaro, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Tesaro, Inc.'s pipeline products Reasons to buy - Evaluate Tesaro, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Tesaro, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Tesaro, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Tesaro, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tesaro, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Tesaro, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Tesaro, Inc. Snapshot 5 Tesaro, Inc. Overview 5 Key Information 5 Key Facts 5 Tesaro, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Tesaro, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Tesaro, Inc. - Pipeline Products Glance 11 Tesaro, Inc. - Late Stage Pipeline Products 11 Pre-Registration Products/Combination Treatment Modalities 11 Phase III Products/Combination Treatment Modalities 12 Tesaro, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Tesaro, Inc. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Tesaro, Inc. - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 Tesaro, Inc. - Drug Profiles 17 rolapitant hydrochloride 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 niraparib 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 SCH-900978 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 TSR-011 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibody to Inhibit LAG-3 for Cancer 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody to Inhibit PD-1 and LAG-3 for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody to Inhibit PD-1 and TIM-3 for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Monoclonal Antibody to Inhibit TIM-3 for Cancer 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 TSR-042 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Tesaro, Inc. - Pipeline Analysis 27 Tesaro, Inc. - Pipeline Products by Target 27 Tesaro, Inc. - Pipeline Products by Route of Administration 29 Tesaro, Inc. - Pipeline Products by Molecule Type 30 Tesaro, Inc. - Pipeline Products by Mechanism of Action 31 Tesaro, Inc. - Recent Pipeline Updates 33 Tesaro, Inc. - Dormant Projects 39 Tesaro, Inc. - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 42 Disclaimer 42
List of Tables Tesaro, Inc., Key Information 5 Tesaro, Inc., Key Facts 5 Tesaro, Inc. - Pipeline by Indication, 2014 8 Tesaro, Inc. - Pipeline by Stage of Development, 2014 9 Tesaro, Inc. - Monotherapy Products in Pipeline, 2014 10 Tesaro, Inc. - Pre-Registration, 2014 11 Tesaro, Inc. - Phase III, 2014 12 Tesaro, Inc. - Phase II, 2014 13 Tesaro, Inc. - Phase I, 2014 14 Tesaro, Inc. - Preclinical, 2014 15 Tesaro, Inc. - Unknown, 2014 16 Tesaro, Inc. - Pipeline by Target, 2014 28 Tesaro, Inc. - Pipeline by Route of Administration, 2014 29 Tesaro, Inc. - Pipeline by Molecule Type, 2014 30 Tesaro, Inc. - Pipeline Products by Mechanism of Action, 2014 32 Tesaro, Inc. - Recent Pipeline Updates, 2014 33 Tesaro, Inc. - Dormant Developmental Projects,2014 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.